New approaches in hormone refractory prostate cancer

被引：13

作者：

Sonpavde, G ^{[1
]}

Hutson, TE ^{[1
]}

机构：

[1] US Oncol Res Network, Houston, TX USA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2006年 / 29卷 / 02期

关键词：

hormone refractory prostate cancer; chemotherapy; targeted therapy; biological therapy;

D O I：

10.1097/01.coc.0000197667.67678.9e

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Effective therapeutic options have not existed for prostate cancer progressing after androgen deprivation therapy until very recently. Docetaxel based chemotherapy has been demonstrated to extend survival in 2 large randomized trials. These studies have provided the impetus to combine docetaxel with novel biologic agents to further consolidate the gains in long-term outcome. With the arrival of exciting agents including vaccines, monoclonal antibodies, bone-targeted drugs, antisense oligonucleotides, antiangiogenic drugs, and small molecule receptor tyrosine kinase inhibitors, the future of prostate cancer therapy appears promising.

引用

页码：196 / 201

页数：6

共 64 条

[1]

BANDER NH, 2005, J CLIN ONCOL

[2] Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer [J].

Beer, TM ;

Eilers, KM ;

Garzotto, M ;

Egorin, MJ ;

Lowe, BA ;

Henner, WD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :123-128

[3]

BEER TM, 2005, P AM SOC CLIN ONCOL

[4]

Bubley, 2000, J CLIN ONCOL, V18, P2644

[5] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].

Bubley, GJ ;

Carducci, M ;

Dahut, W ;

Dawson, N ;

Daliani, D ;

Eisenberger, M ;

Figg, WD ;

Freidlin, B ;

Halabi, S ;

Hudes, G ;

Hussain, M ;

Kaplan, R ;

Myers, C ;

Oh, W ;

Petrylak, DP ;

Reed, E ;

Roth, B ;

Sartor, O ;

Scher, H ;

Simons, J ;

Sinibaldi, V ;

Small, EJ ;

Smith, MR ;

Trump, DL ;

Vollmer, R ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467

[6] Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group [J].

Canil, CM ;

Moore, MJ ;

Winquist, E ;

Baetz, T ;

Pollak, M ;

Chi, KN ;

Berry, S ;

Ernst, DS ;

Douglas, L ;

Brundage, M ;

Fisher, B ;

McKenna, A ;

Seymour, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :455-460

[7] Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer [J].

D'Amico, AV ;

Moul, J ;

Carroll, PR ;

Sun, L ;

Lubeck, D ;

Chen, MH .

JOURNAL OF UROLOGY, 2005, 173 (05) :1572-1576

[8] Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer [J].

Dahut, WL ;

Gulley, JL ;

Arlen, PM ;

Liu, Y ;

Fedenko, KM ;

Steinberg, SM ;

Wright, JJ ;

Parnes, H ;

Chen, CC ;

Jones, E ;

Parker, CE ;

Linehan, WM ;

Figg, WD .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2532-2539

[9]

DAVIS TA, 2002, P AM SOC CLIN ONCOL

[10] Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials [J].

Dawson, NA .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3398-3405

← 1 2 3 4 5 6 7 →